Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (581-590 of 671) with videos related to

Pageof 68
Sort By:
Frontiers in Immunology|November 28, 2022
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignanciesHarjeet Singh, Samer A Srour, Denái R Milton, et al.
Bone Marrow Transplantation|May 24, 2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantationBorje S Andersson, Peter F Thall, Junsheng Ma, et al.
Blood|November 4, 2015
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancyCraig Kollman, Stephen R Spellman, Mei-Jie Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2016
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell TransplantationFabian Bock, Gary Lu, Samer A Srour, et al.
Leukemia & Lymphoma|October 13, 2011
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplantStefan O Ciurea, Rima M Saliba, Nelson Hamerschlak, et al.
Journal of Hematology & Oncology|January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureNicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Blood Advances|January 10, 2022
Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvementSerkan Akin, Chitra Hosing, Issa Khouri, et al.
Transplantation and Cellular Therapy|May 9, 2021
Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell LymphomaJacinth Joseph, Junsheng Ma, Fady Hennawy, et al.
Cancer|April 13, 2018
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000Hagop M Kantarjian, Courtney D DiNardo, Graciela M Nogueras-Gonzalez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2018
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34<sup>+</sup> Selected and Unmodified Hematopoietic Stem Cell TransplantationRoni Tamari, Betul Oran, Patrick Hilden, et al.
Pageof 68

Showing results (581-590 of 671) with videos related to

Sort By:
Pageof 68
Frontiers in Immunology|November 28, 2022
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignanciesHarjeet Singh, Samer A Srour, Denái R Milton, et al.
Bone Marrow Transplantation|May 24, 2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantationBorje S Andersson, Peter F Thall, Junsheng Ma, et al.
Blood|November 4, 2015
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancyCraig Kollman, Stephen R Spellman, Mei-Jie Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2016
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell TransplantationFabian Bock, Gary Lu, Samer A Srour, et al.
Leukemia & Lymphoma|October 13, 2011
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplantStefan O Ciurea, Rima M Saliba, Nelson Hamerschlak, et al.
Journal of Hematology & Oncology|January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureNicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Blood Advances|January 10, 2022
Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvementSerkan Akin, Chitra Hosing, Issa Khouri, et al.
Transplantation and Cellular Therapy|May 9, 2021
Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell LymphomaJacinth Joseph, Junsheng Ma, Fady Hennawy, et al.
Cancer|April 13, 2018
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000Hagop M Kantarjian, Courtney D DiNardo, Graciela M Nogueras-Gonzalez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2018
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34<sup>+</sup> Selected and Unmodified Hematopoietic Stem Cell TransplantationRoni Tamari, Betul Oran, Patrick Hilden, et al.
Pageof 68